Chemdiv, Inc.

Chemdiv, Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

ChemDiv, a fully Integrated Target-to-Market Contract Research Organization (CRO) headquartered in San Diego, CA USA. ChemDiv provides integrated drug discovery and early clinical development deliverables by extracting added value from potential therapeutic candidates via rapid, streamlined outcomes and effective use of capital. - 25 years experience and 2500 customers worldwide - Premium R&D CRO based in USA with global reach - Seasoned project managers - Extensive Academic partnerships - Flexible business models - Competitive pricing options - Industry's largest ever-greening stock compound inventory - Ongoing investments in novel proprietary chemistry and discovery platforms One of the oldest CROs in the industry, ChemDiv provides Integrated Discovery outSource™ solutions that cover the complete range of disciplines needed to bring new drugs for treatment of CNS, oncology, inflammation, metabolic and infectious diseases from target to candidate and through clinical Proof of Concept to the market. ChemDiv champions collaborative development models with co-investors to rescue under-exploited R&D assets for pharmaceutical and biotech partners. #pharma #biotech #chemistry #screening_Libraries #drug_discovery_services

Company Details

Employees
61
Founded
-
Address
6605 Nancy Ridge Drive, San Diego,ca 92121,united States
Phone
(858)794-4931
Industry
Research Services
NAICS
Scientific Research and Development Services
Research and Development in the Physical, Engineering, and Life Sciences
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
HQ
San Diego, CA
Looking for a particular Chemdiv, Inc. employee's phone or email?

Chemdiv, Inc. Questions

News

ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics - PR Newswire

ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics PR Newswire

ChemDiv Extends Discovery and Early Development Partnership with Mondego Bio on Best-in-Class PTPN2 Immuno-Oncology Program - Lelezard

ChemDiv Extends Discovery and Early Development Partnership with Mondego Bio on Best-in-Class PTPN2 Immuno-Oncology Program Lelezard

Fragment Libraries from Large and Novel Synthetic Compounds and Natural Products: A Comparative Chemoinformatic Analysis - ACS Publications

Fragment Libraries from Large and Novel Synthetic Compounds and Natural Products: A Comparative Chemoinformatic Analysis ACS Publications

Discovery of potential novel TRPC5 inhibitors by virtual screening and bioassay - ScienceDirect.com

Discovery of potential novel TRPC5 inhibitors by virtual screening and bioassay ScienceDirect.com

Carbenoid-involved reactions integrated with scaffold-based screening generates a Nav1.7 inhibitor - Nature

Carbenoid-involved reactions integrated with scaffold-based screening generates a Nav1.7 inhibitor Nature

ChemDiv Marks a Milestone as Orionis Biosciences' Novel Immunotherapy Enters Phase I Clinical Trials - BioSpace

ChemDiv Marks a Milestone as Orionis Biosciences' Novel Immunotherapy Enters Phase I Clinical Trials BioSpace

Integration of molecular modelling and in vitro studies to inhibit LexA proteolysis - Frontiers

Integration of molecular modelling and in vitro studies to inhibit LexA proteolysis Frontiers

Consensus docking aid to model the activity of an inhibitor of DNA methyltransferase 1 inspired by de novo design - Frontiers

Consensus docking aid to model the activity of an inhibitor of DNA methyltransferase 1 inspired by de novo design Frontiers

Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2 - ScienceDirect.com

Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2 ScienceDirect.com

Identifying inhibitors of β-haematin formation with activity against chloroquine-resistant Plasmodium falciparum malaria parasites via virtual screening approaches - Nature

Identifying inhibitors of β-haematin formation with activity against chloroquine-resistant Plasmodium falciparum malaria parasites via virtual screening approaches Nature

Combining generative artificial intelligence and on-chip synthesis for de novo drug design - Science | AAAS

Combining generative artificial intelligence and on-chip synthesis for de novo drug design Science | AAAS

In silico high-throughput screening system for AKT1 activators with therapeutic applications in sepsis acute lung injury - Frontiers

In silico high-throughput screening system for AKT1 activators with therapeutic applications in sepsis acute lung injury Frontiers

AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial - medRxiv

AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial medRxiv

Discovery of SIRT7 Inhibitor as New Therapeutic Options Against Liver Cancer - Frontiers

Discovery of SIRT7 Inhibitor as New Therapeutic Options Against Liver Cancer Frontiers

Discovery of Novel IDH1 Inhibitor Through Comparative Structure-Based Virtual Screening - Frontiers

Discovery of Novel IDH1 Inhibitor Through Comparative Structure-Based Virtual Screening Frontiers

Top Chemdiv, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant